Brain – V9: 2023+
| Primary Site | Histology | Behavior | Year of Diagnosis |
|---|---|---|---|
| C700, C710-C719 | 8000-8803, 8810-8858, 8860-8900, 8902-8905, 8921, 8932-8934, 8940-8990, 8992, 9000-9016, 9030-9043, 9045-9221, 9230, 9240-9361, 9363-9365, 9370-9460, 9480-9500, 9505-9507, 9509-9580, 9582, 9671, 9680, 9690, 9699, 9702-9715, 9719, 9749, 9751-9759, 9766 | <Any value> | 2023-9998, 9999, <BLANK> |
| C700, C710-C719 | 8804-8806, 8859, 8901, 8910-8920, 8930-8931, 8935-8936, 8991, 9020, 9044, 9222, 9231, 9366-9368, 9581, 9590-9663, 9673-9679, 9687-9689, 9691-9698, 9700-9701, 9716-9718, 9724-9742, 9761-9765, 9767-9993 | 0, 1 | 2023-9998, 9999, <BLANK> |
Notes
Any behavior:
- 8000-8803, 8810-8858, 8860-8900, 8902-8905, 8921, 8932-8934, 8940-8990, 8992, 9000-9016, 9030-9043, 9045-9221, 9230, 9240-9361, 9363-9365, 9370-9460, 9480-9500, 9505-9507, 9509-9580, 9582, 9671, 9680, 9690, 9699, 9702-9715, 9719, 9749, 9751-9759, 9766
Benign/Borderline histologies (/0, /1):
- 8804-8806, 8859, 8901, 8910-8920, 8930-8931, 8935-8936, 8991, 9020, 9044, 9222, 9231, 9366-9368, 9581, 9590-9663, 9673-9679, 9687-9689, 9691-9698, 9700-9701, 9716-9718, 9724-9742, 9761-9765, 9767-9993
C700 Cerebral meninges
C710 Cerebrum
C711 Frontal lobe
C712 Temporal lobe
C713 Parietal lobe
C714 Occipital lobe
C715 Ventricle, NOS
C716 Cerebellum, NOS
C717 Brain stem
C718 Overlapping lesion of brain
C719 Brain, NOS
Note 1: Sources used in the development of this schema
- SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)
- SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)
- Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx
- Brain and Spinal Cord, from the AJCC Cancer Staging System Version 9 (2022). Used with permission of the American College of Surgeons, Chicago, Illinois.
Note 2: Other EOD Schemas with Brain sites
- All histologies with behavior /0 and /1 are captured in this schema, for behavior /3, see the following schemas for the listed histologies
- GIST: 8935-8936
- Lymphoma: * 9590, 9596-9663, 9673-9679, 9687-9689, 9691-9698, 9716-9718, 9725-9726, 9735, 9737-9738, 9826-9827:
- Mycosis Fungoides: 9700-9701
- Plasma Cell Disorders: 9731, 9734, 9761
- Soft Tissue Rare: 8804-8806, 8859, 8901, 8910-8920, 8930-8931, 8991, 9020, 9044, 9222, 9231, 9366-9368, 9581
Note 3: Medulloblastoma
- For diagnoses January 1, 2023, and forward, the following histologies will be collected in the Medulloblastoma EOD schema
- 9362, 9470-9478, 9501-9504, 9508
- Exception: For C723 and 9473/3, see Orbital Sarcoma
Note 4: Summary Stage
- Summary Stage is the only applicable staging system for this site/histology/schema.
Data Items
| Name | Default Value | Used in Derivation | NAACCR Item | Required By | Metadata |
|---|---|---|---|---|---|
| Year of Diagnosis | <BLANK> | Yes |
NAACCR #390
dateOfDiagnosis |
None | |
| Primary Site | <BLANK> | Yes |
NAACCR #400
primarySite |
None | |
| Histology | <BLANK> | Yes |
NAACCR #522
histologicTypeIcdO3 |
None | |
| Behavior | <BLANK> | Yes |
NAACCR #523
behaviorCodeIcdO3 |
None | |
| Tumor Size Clinical | <BLANK> | No |
NAACCR #752
tumorSizeClinical |
None | |
| Tumor Size Pathological | <BLANK> | No |
NAACCR #754
tumorSizePathologic |
None | |
| Tumor Size Summary | 999 | No |
NAACCR #756
tumorSizeSummary |
None | |
| Regional Nodes Positive | 99 | No |
NAACCR #820
regionalNodesPositive |
None | |
| Regional Nodes Examined | 99 | No |
NAACCR #830
regionalNodesExamined |
None | |
| Neoadjuvant Therapy | 9 | No |
NAACCR #1632
neoadjuvantTherapy |
None | |
| Neoadjuvant Therapy – Clinical Response | 9 | No |
NAACCR #1633
neoadjuvTherapyClinicalResponse |
None | |
| Neoadjuvant Therapy – Treatment Effect | 9 | No |
NAACCR #1634
neoadjuvTherapyTreatmentEffect |
None | |
| EOD Primary Tumor | 999 | Yes |
NAACCR #772
eodPrimaryTumor |
None | |
| EOD Regional Nodes | 888 | Yes |
NAACCR #774
eodRegionalNodes |
None | |
| EOD Mets | 00 | Yes |
NAACCR #776
eodMets |
None | |
| SS2018 | <BLANK> | No |
NAACCR #764
summaryStage2018 |
None | |
| Grade Clinical | 9 | Yes |
NAACCR #3843
gradeClinical |
All | SSDI |
| Grade Pathological | 9 | Yes |
NAACCR #3844
gradePathological |
All | SSDI |
| Grade Post Therapy Clin (yc) | <BLANK> | No |
NAACCR #1068
gradePostTherapyClin |
COC NPCR SEER |
SSDI |
| Grade Post Therapy Path (yp) | <BLANK> | No |
NAACCR #3845
gradePostTherapy |
CCCR/Canada COC NPCR SEER |
SSDI |
| Brain Molecular Markers | 88 | No |
NAACCR #3816
brainMolecularMarkers |
NPCR SEER |
SSDI |
| Chromosome 1p Status | 8 | No |
NAACCR #3801
chromosome1pLossHeterozygosity |
COC SEER |
SSDI |
| Chromosome 19q Status | 8 | No |
NAACCR #3802
chromosome19qLossHeterozygosity |
COC SEER |
SSDI |
| MGMT | 8 | No |
NAACCR #3889
methylationOfO6MGMT |
COC SEER |
SSDI |
| Brain Primary Tumor Location | <BLANK> | No |
NAACCR #3964
brainPrimaryTumorLocation |
CCCR/Canada 2024– COC 2024– NPCR 2024– SEER 2024– |
SSDI 2024– |